Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  European Journal of Pharmacology

• Publication date

  2001-05-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0014-2999(01)00959-1PMID 11348632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and structure–activity investigation of novel vasopressin hypotensive peptide agonists

  1999cited by this paper
• Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity.

  1999cited by this paper
• Discovery and design of novel vasopressin hypotensive peptide agonists.

  1999cited by this paper
• Discovery of Novel Selective Hypotensive Vasopressin Peptides

  1998cited by this paper
• Discovery of novel selective hypotensive vasopressin peptides. A new vasodilating vasopressin receptor?

  1998cited by this paper
• Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors

  1998cited by this paper
• pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM

  1997cited by this paper
• Position Three in Vasopressin Antagonist Tolerates Conformationally Restricted and Aromatic Amino Acid Substitutions: A Striking Contrast with Vasopressin Agonists

  1997cited by this paper
• On the Mechanism of Hormone Recognition and Binding by the CCK‐B/Gastrin Receptor

  1997cited by this paper
• V2 Receptor‐Mediated Vasodilation in Healthy Humans

  1995cited by this paper
• Effects of arginine vasopressin and 1‐desamino‐8‐D arginine vasopressin on forearm vasculature of healthy subjects and patients with a V2 receptor defect

  1995cited by this paper
• Control of renal medullary blood flow by vasopressin V1 and V2 receptors.

  1995cited by this paper
• L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs.

  1994cited by this paper
• Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.

  1993cited by this paper
• Endothelium-dependent vasorelaxation evoked by desmopressin and involvement of nitric oxide in rat aorta.

  1993cited by this paper
• Nitric oxide is a mediator of hypoxic coronary vasodilatation. Relation to adenosine and cyclooxygenase-derived metabolites.

  1992cited by this paper
• Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

  1989cited by this paper
• Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

  1988cited by this paper
• Evidence for a vasodilatory effect of vasopressin in the conscious rat.

  1986cited by this paper
• Solid Phase Peptide Synthesis

  1984cited by this paper
• Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin.

  1982cited by this paper
• (1-Beta-mercapto-beta,beta-diethylpropionic acid)-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin.

  1974cited by this paper
• Synthetic analogs of oxytocin and the vasopressins.

  1973cited by this paper
• SOLID-PHASE PEPTIDE SYNTHESIS. 3. AN IMPROVED SYNTHESIS OF BRADYKININ.

  1964cited by this paper
• Biologic assays for oxytocin and vasopressin.

  1961cited by this paper
• Biologic assays for oxytocin and vasopressin.

  1961cited by this paper
• A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract.

  1948cited by this paper

• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cites this paper
• Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

  2007cites this paper
• The Role of the Merrifield Solid Phase Method in the Discovery and Exploration of a New Class of Selective Vasopressin Hypotensive Agonists

  2007cites this paper
• Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin‐induced dysmenorrhea

  2006cites this paper
• Design and synthesis of potent, highly selective vasopressin hypotensive agonists

  2006influential citation
• A comparison between haemodynamic effects of vasopressin analogues

  2004cites this paper
• Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women

  2004cites this paper
• A novel vasopressin peptide lowers blood pressure through decreases in cardiac output.

  2003cites this paper